Siemens Healthineers Slovakia
Zobrazovacia diagnostika
Molecular Imaging
Radiopharma
Investing in Global Radiopharma Infrastructure

Investing in Global Radiopharma InfrastructureA growing global network designed to deliver reliability, expand access, and support the next generation of molecular imaging.

Infrastructure built to deliver

Inside our growing network

Radiopharma manufacturing facility in Ivrea, Italy

Ivrea, Italy

Strengthening our radiopharmaceutical network in Italy, the Ivrea manufacturing facility expands access to PET imaging across key northern regions. As the third site in the country, it is built for localized, high-efficiency production aligned with clinical demand. With increased capacity, optimized operational flows, and a restored cyclotron, the facility ensures reliable supply and timely delivery to hospitals and imaging centers.

Radiopharma manufacturing facility in San Diego

San Diego, United States

The San Diego manufacturing facility introduces the first solid target manufacturing lab in our network, advancing theranostics readiness and innovation. Purpose-built to support emerging radioligand therapies, the facility strengthens our ability to develop and manufacture next-generation tracers. With specialized infrastructure designed for parallel production, the site enables reliable supply while supporting the growing demand for precision diagnostics and targeted treatments.

Radiopharma manufacturing facility in Salamanca, Spain

Salamanca, Spain

Advancing our Radiopharma network in Europe, the Salamanca manufacturing facility represents one of the most technologically advanced facilities in our network. Strategically positioned to serve a broad region across Spain and into Portugal, it expands access to PET imaging for a growing patient population. With next-generation hot cell technology and integrated visual inspection processes aligned with the latest Annex 1 GMP requirements, the site sets a new standard for quality, compliance, and operational excellence in radiopharmaceutical production.

Radiopharma manufacturing facility in Dunstable, UK. Known as the 8X radiopharmacy with 8 times the capacity of a standard Radiopharma site.

Dunstable, United Kingdom

Built as the first 8X radiopharmacy in the UK, our new Dunstable manufacturing facility delivers eight times the capacity of a standard Radiopharma site, strengthening the supply of PET radiopharmaceuticals for the NHS as demand continues to grow. With built-in redundancy and resilience throughout, it is designed to provide a reliable, regular supply and same-day delivery to PET/CT centers across the UK.

Radiopharma manufacturing facility in Ivrea, Italy

Ivrea, Italy

Strengthening our radiopharmaceutical network in Italy, the Ivrea manufacturing facility expands access to PET imaging across key northern regions. As the third site in the country, it is built for localized, high-efficiency production aligned with clinical demand. With increased capacity, optimized operational flows, and a restored cyclotron, the facility ensures reliable supply and timely delivery to hospitals and imaging centers.

Radiopharma manufacturing facility in San Diego

San Diego, United States

The San Diego manufacturing facility introduces the first solid target manufacturing lab in our network, advancing theranostics readiness and innovation. Purpose-built to support emerging radioligand therapies, the facility strengthens our ability to develop and manufacture next-generation tracers. With specialized infrastructure designed for parallel production, the site enables reliable supply while supporting the growing demand for precision diagnostics and targeted treatments.

Radiopharma manufacturing facility in Salamanca, Spain

Salamanca, Spain

Advancing our Radiopharma network in Europe, the Salamanca manufacturing facility represents one of the most technologically advanced facilities in our network. Strategically positioned to serve a broad region across Spain and into Portugal, it expands access to PET imaging for a growing patient population. With next-generation hot cell technology and integrated visual inspection processes aligned with the latest Annex 1 GMP requirements, the site sets a new standard for quality, compliance, and operational excellence in radiopharmaceutical production.

Radiopharma manufacturing facility in Dunstable, UK. Known as the 8X radiopharmacy with 8 times the capacity of a standard Radiopharma site.

Dunstable, United Kingdom

Built as the first 8X radiopharmacy in the UK, our new Dunstable manufacturing facility delivers eight times the capacity of a standard Radiopharma site, strengthening the supply of PET radiopharmaceuticals for the NHS as demand continues to grow. With built-in redundancy and resilience throughout, it is designed to provide a reliable, regular supply and same-day delivery to PET/CT centers across the UK.

Radiopharma manufacturing facility in Ivrea, Italy

Ivrea, Italy

Strengthening our radiopharmaceutical network in Italy, the Ivrea manufacturing facility expands access to PET imaging across key northern regions. As the third site in the country, it is built for localized, high-efficiency production aligned with clinical demand. With increased capacity, optimized operational flows, and a restored cyclotron, the facility ensures reliable supply and timely delivery to hospitals and imaging centers.

Expanding our footprint

United States expansion underway

Europe expansion underway

Radiopharma CDMO vial

Supporting innovation at scale

A strong CDMO partnership can help transform promising innovations into reliable patient access. Our global infrastructure, operational expertise, and commitment to quality help partners:

Scale with confidence by expanding production and distribution while maintaining consistent, compliant supply.
Reduce operational risk through proven manufacturing readiness, quality systems, and supply chain expertise.
Accelerate commercialization with support spanning technology transfer, regulatory documentation, and routine production.

This approach helps IP holders bring innovative radiopharmaceuticals to more patients with confidence and reliability.

Pomohli vám tieto informácie?